BTIG Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $40

Benzinga Newsdesk www.benzinga.com Neutral 58.1%

Neg 0% Neu 58.1% Pos 0%

BTIG analyst Thomas Shrader initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $40.